Key Takeaways
- Robigo secures Series A funding led by Leaps by Bayer to advance microbial biopesticides for crops.
- The ARGO platform enables rapid development of crop protection solutions targeting multiple soil-borne pathogens.
- Robigo aims to enhance sustainability in agriculture by providing effective, engineered biological solutions without altering farming practices.
Innovative Solutions in Crop Protection
Robigo, a biotechnology company, has announced an undisclosed Series A funding round led by Leaps by Bayer, with participation from Illumina Ventures, SVG Thrive, Congruent Ventures, and Endeavor8. The investment will help Robigo launch microbial biopesticides aimed at controlling fungal diseases in soybeans and specialty crops in the U.S., while also expanding its pipeline to combat additional soil-borne pathogens in a market valued at $10 billion.
The ARGO platform, developed by Robigo, distinguishes itself through its scalability rather than focusing on a single product. Dr. Juergen Eckhardt of Leaps by Bayer highlighted that Robigo is establishing a versatile “engine” for addressing various pathogens in broadacre crops, utilizing synthetic biology and computational design. This innovative technology can silence essential genes in pathogens, significantly reducing development time from the typical three to five years to less than 20 months.
Biological crop protection products have faced challenges regarding efficacy, consistency, and cost. Robigo’s engineering-focused approach aims to overcome these hurdles by employing synthetic biology. Eckhardt emphasized that Robigo is not merely discovering new products but is engineering solutions that meet expectations on performance and cost-effectiveness, ultimately addressing the longstanding issues in biological protection.
Robigo’s products are intended for one-time applications, allowing engineered microbes to produce active ingredients throughout the growing season without altering existing farming practices. The company’s initial focus is on economically significant diseases, such as Sudden Death Syndrome (SDS) in soybeans, which incurs estimated losses of $200 million to $500 million annually, and fusarium wilt affecting lettuce and berry producers.
Robigo’s founder and CEO, Dr. Andee Wallace, articulated the company’s mission to ensure growers do not have to compromise on effectiveness, affordability, or sustainability. The company aims to blend nature’s foundation with advanced engineering to produce viable biological options.
In terms of commercialization, Robigo is pursuing a dual strategy: developing proprietary products and engaging in strategic partnerships. Eckhardt noted that both paths offer complementary value, positioning Robigo as a lucrative partner for larger agricultural firms seeking innovative solutions without the need for internal development.
Robigo’s work also showcases the intersection of biological crop protection and synthetic biology. Although the products utilize genetically engineered microorganisms, they remain categorized as biologicals due to the active agents being living microbes. This innovative approach aims to not only improve consistency and performance in crop protection but also to redefine perceptions of biological solutions in agriculture.
The content above is a summary. For more details, see the source article.